IP Library › Granted Patent US 12,516,121
Granted Patent B2
US 12,516,121 · App. 17/625,551 · Granted Jan 6, 2026

Antibodies to human programmed death receptor PD-1

Inventors: Sanjeev Kumar Mendiratta (Gujarat, IN); Kaushik Banerjee (Gujarat, IN); Dipti Mehta (Gujarat, IN); Ramkrashan Kasera (Gujarat, IN); Arun Singh (Gujarat, IN); Aashini Parikh (Gujarat, IN); Pankaj Kalita (Gujarat, IN); Rutu Paraschandra Dave (Gujarat, IN); Vibhuti Sharma (Gujarat, IN); Hardik Pandya (Gujarat, IN)
Assignee: ZYDUS LIFESCIENCES LIMITED
C07K16/2818A61K47/6849A61K51/1027C07K16/2803C07K16/2827C07K16/32C07K2317/24C07K2317/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,121
App. No.
17/625,551
Granted
Jan 6, 2026
Kind
B2
Abstract

The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.

Claims (2)

1 . An anti-PD-1 antibody or antigen binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 149 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 152, wherein the anti-PD-1 antibody comprising IgG4 constant region having amino acid sequence of SEQ ID NO: 153 comprising the single amino acid substitution S228P, P329G, M428L and N434S.

2 . A composition comprising the antibody, or antigen-binding portion thereof, of claim 1 , and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Nov 20, 2023
From: CADILA HEALTHCARE LIMITED
To: ZYDUS LIFESCIENCES LIMITED
Reel/Frame 065618/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2022
From: MENDIRATTA, SANJEEV KUMAR; BANERJEE, KAUSHIK; MEHTA, DIPTI; KASERA, RAMKRASHAN; SINGH, ARUN; PARIKH, AASHINI; KALITA, PANKAJ; DAVE, RUTU PARASCHANDRA; SHARMA, VIBHUTI; PANDYA, HARDIK
To: CADILA HEALTHCARE LIMITED
Reel/Frame 059452/0278 →
Priority Claims (1)
IN 201921027443 · Jul 9, 2019 · national
Continuity (1)
Related Publication 20220289846A1 · Sep 15, 2022
References Cited (28)
US 9492539B2 · Korman et al. · 2016 [cited by applicant]
US 20160159905A1 · Abdiche et al. · 2016 [cited by applicant]
US 20170247454A1 · Benz et al. · 2017 [cited by applicant]
US 20170334995A1 · Zettl et al. · 2017 [cited by applicant]
US 20180222965A1 · Lazar · 2018 [cited by applicant]
US 20190127467A1 · Shah et al. · 2019 [cited by applicant]
EP 3176180A1 · 2017 [cited by applicant]
WO 2016015685A1 · 2016 [cited by applicant]
WO 2017011580A2 · 2017 [cited by applicant]
WO 2017207628A1 · 2017 [cited by applicant]
WO 2018071792A1 · 2018 [cited by applicant]
WO 2018087143A2 · 2018 [cited by applicant]
International Search Report; International Application No. PCT/IB2020/056458; International Filing Date—Jul. 9, 2020; Date of Mailing—Oct. 28, 2020; 11 pages. [cited by applicant]
Written Opinion; International Application No. PCT/IB2020/056458; International Filing Date—Jul. 9, 2020; Date of Mailing—Oct. 28, 2020; 13 pages. [cited by applicant]
Angal S, et al.; “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”; Mol Immunol, vol. 30, Issue No. 1; pp. 105-108 (1993). [cited by applicant]
Brockmann et al.; “Synthetic single-framework antibody library integrated with rapid affinity maturation by VL shuffling”; Protein Engineering, Design & Selection vol. 24, Issue No. 9; pp. 691-700 (2011). [cited by applicant]
Brown, et al.; “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production”; J Immunol, vol. 170; pp. 1257-1266 (2003). [cited by applicant]
Chen et al., “Generation and Analysis of Random Point Mutations in an Antibody CDR2 Sequence: Many Mutated Antibodies Lose Their Ability to Bind Antigen” J. Exp. Med. The Rockefeller University Press, vol. 176, pp. 855-… [cited by applicant]
Dong et al.; “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion”; Nature Med, vol. 5, Issue No. 12; pp. 1365-1369 (1999). [cited by applicant]
Huovinen, T. et al.; “Primer Extension Mutagenesis Powered by Selective Rolling Circle Amplification”; PLoS One, vol. 7, Issue No. 2, e31817; 9 pages (2012). [cited by applicant]
Iwai, Y. et al.; “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade”; PNAS USA, vol. 99, Issue No. 99; pp. 12293-12297 (2002). [cited by applicant]
Karachaliou, N. et al.; “Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients”; Ther Adv Med Oncol, vol. 10; pp. 1-23; DOI: 10.1177/17588340… [cited by applicant]
Palucka, K. et al.; “Dendritic Cells as the Terminal Stage of Monocyte Differentiation”; J Immunol, vol. 160, Issue No. 9; pp. 4587-4595; DOI: 10.4049/jimmunol.160.9.4587 (1998). [cited by applicant]
Peng, W. et al.; “PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-y Inducible Chemokines”; Cancer Res, vol. 72, Issue No. 20; pp. 5209-5218 (2012). [cited by applicant]
Rudikoff et al., “Single amino acid substitution alerting antigen-binding specificity”, Proc. Natl. Acad. Sci USA, vol. 79, pp. 1979-1983, Mar. 1982. [cited by applicant]
Sheridan et al.; “Cautious optimism surrounds early clinical data for PD-1 blocker”; Nature Biotechnology, vol. 30; pp. 729-730 (2012). [cited by applicant]
Zou et al.; “Inhibitory B7-family molecules in the tumour microenvironment”; Nature Review Immunol, vol. 8, Issue No. 6; pp. 467-477 (2008). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1979-1983, Mar. 1982. [cited by applicant]